Business Wire

CA-JUNIPER-NETWORKS

23.1.2023 09:01:52 CET | Business Wire | Press release

Share
Juniper Networks Chosen to Upgrade Virgin Media O2’s Core IP Backbone Network to 800G Readiness

Juniper Networks (NYSE: JNPR), a leader in secure, AI-driven networks, today announced that Virgin Media O2, one of the UK’s largest fixed and mobile service providers with approximately 50 million online media connections, successfully upgraded its IP core backbone network with Juniper – capable of supporting 800G. Virgin Media O2 is investing in sustainable infrastructure for the long term that can support sustained data growth and bandwidth demands. Its investment underpins the rapid introduction of revenue-generating services while delivering significantly-reduced power, cooling and space consumption and costs.

Consistently good user experience is a fundamental benchmark of success. As its 5G and network expansion continues, Virgin Media O2 turned to Juniper to build a network that is 400G-enabled and 800G-ready to create a near future-proofed digital foundation for its customers. Virgin Media O2 selected Juniper as the technology partner for this strategic upgrade for numerous reasons, including its previous track record as a key networking provider for more than ten years with Virgin Media and O2 before their joint venture in 2021. Another significant factor was Juniper’s ability to deliver compelling economics for Virgin Media O2. These include long-term investment protection through continuous custom silicon innovation by keeping pace with market demands, the planned use of automation tools to help reduce operational costs and a favorable Total Cost of Ownership (TCO) with a reduced energy consumption design.

News Highlights

  • In the past year, Virgin Media O2 has seen 32 percent traffic growth on its mobile network, 16 percent growth in broadband data downloads and a peak traffic load of 22TB, underlining the need for increased data capacity and flexible scalability
  • Virgin Media O2 has successfully migrated all core traffic in its six backbone locations across the UK with Juniper Networks PTX10008 Packet Transport Routers, which are purpose-built to deliver cloud-optimized network transformation at scale and with operational flexibility
  • The modular PTX10008 routers deliver reduced resource consumption as a result of inherently-sustainable design features, including front-to-back cooling, flexible power supplies that can use either high- or low-power modes and high-density port capability that enables optimized throughput in a compact form factor
  • Scalable, secure 400G capability is achieved through ultra-high port density, native inline MACSec encryption on all ports, coupled with the latest generation of ASIC innovation that powers a range of line cards
  • PTX10008 routers support 400G coherent optical transceivers (400G ZR and ZR+) without any density loss today, and are 800G-capable with upgradeability to 800G in the future with silicon innovation and easily-exchanged line cards in the chassis
  • Virgin Media O2’s infrastructure will be underpinned by Juniper’s single operating system, Junos® OS Evolved. This will provide ongoing continuity for streamlined operations.

Supporting Quotes

“Virgin Media O2’s stated ambition is to ‘upgrade the UK’, providing fast, seamless broadband access and mobile services to as many homes and businesses as possible. This calls for responsible, strategic innovation and investment to create an agile network infrastructure that can simultaneously scale in step with our business, be mindful of resource consumption and deliver an extended lifecycle that protects our investment. Juniper is a long-standing technology partner, so it is very reassuring that it has the same vision for sustainable growth, user experience and the fundamental importance of digital enablement in our communities and economy.”

- Jeanie York, Chief Technology Officer, Virgin Media O2

“Service providers face a complex set of technical and commercial challenges that can be contradictory, even intractable—and likely only to multiply in the future—without the right approach. Virgin Media O2 has chosen to leverage silicon, software and automation innovation from Juniper that can turn complexity on its head to deliver a simplified, more reliable and more sustainable network foundation for its business. This means the company can embrace and accelerate growth and service evolution, safe in the knowledge that its millions of users will continue to be able to enjoy the best digital experiences going forward, whatever demands the future may bring.”

- Raj Yavatkar, Chief Technology Officer, Juniper Networks

Additional Information

Juniper’s Climate Change & Sustainability Pages
CEO Blog: Juniper’s Carbon Neutral Pledge
CTO Blog: Sustainable Networking – The Time is Now
Juniper’s 2022 Corporate Sustainability Report

About Juniper Networks

Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on Twitter, LinkedIn and Facebook.

Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.

Statement of Product Direction

The information on this page may contain Juniper's development and plans for future products, features, or enhancements ("SOPD Information"). SOPD Information is subject to change at any time, without notice. Juniper provides no assurances, and assumes no responsibility, that future products, features, or enhancements will be introduced. In no event should any purchase decision be based upon reliance of timeframes or specifics outlined as part of SOPD Information, because Juniper may delay or never introduce the future products, features, or enhancements.

Any SOPD Information within, or referenced or obtained from, this website by any person does not give rise to any reliance claim, or any estoppel, against Juniper in connection with, or arising out of, any representations set forth in the SOPD Information. Juniper is not liable for any loss or damage (howsoever incurred) by any person in connection with, or arising out of, any representations set forth in the SOPD Information.

Category - Cloud & Service Provider

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230123005101/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye